ARCHIVES

Economic Analysis Finds Erlotinib Marginally Cost-Effective For NSCLC

This article is from The Cancer Letter archive.

Vol. 33 No. 2 | February 26, 2010

Download PDF Visit The Full Archive

Related Articles

Clolar Approved for Pediatric Refractory/Relapsed ALL

January 28, 2005

Dismissed Leukemia Drug Helps CLL, Clinical Trials Find

December 26, 2008

FDA Publishes Two Guidances for Lab-Developed Tests

October 3, 2014

BRM Phase 1-2 Task Orders Awarded

November 21, 1980

Van Etten To Take Over As Director Of UC Irvine Chao Cancer Center

July 25, 2013

Senate confirms Crawford as FDA commissioner.

July 22, 2005